title: Hepatocellular carcinoma following renal transplantation: experience in northern Taiwan.
abstract: BACKGROUND
  Transitional cell carcinomas (TCC) have been reported to be the most common post-renal transplantation malignancy in Taiwan; they are considered to be related to the use of herbal drugs. However, in 2004, hepatocellular carcinoma (HCC) was the most prevalent malignancy at our institute. We therefore extended our observations through 2006 to include a larger renal transplant cohort.
  
  
  METHODS
  Patients were given an immunosuppressive regimen consisting of either cyclosporine or FK 506, mycophenolate mofetil, and copticosteroid. Critical diagnostic follow-up procedures were performed trimonthly. Aggressive surgical procedures were performed when operable cancers were found. Immunosuppressants were reduced thereafter to prevent recurrence.
  
  
  RESULTS
  Among 663 patients, 55 developed 58 malignancies which were diagnosed after a mean of 70 months posttransplantation. Among these 55 patients, 25 died. HCC accounted for 22 malignancies, followed by 15 cases of TCC, and 8 cases of posttransplantation lymphoproliferative disorder (PTLD). Fifteen known hepatitis B carriers received lamivudine therapy; none had recurrences and only 2 acquired HCC. These 2 patients are still living, whereas the remaining 20 subjects with HCC are deceased. Of the 37 patients who received anti-CD25 induction therapy, none displayed PTLD.
  
  
  CONCLUSIONS
  HCC remains the most common post-renal transplantation malignancy in northern Taiwan. The high rates of hepatitis B and C endemic to Taiwan and the prevalence of hepatitis C virus (HCV) genotype 1b infections in northern Taiwan may explain this finding. Frequent alpha-fetoprotein measurements and liver ultrasonograms are recommended for early detection of HCC among Taiwanese renal transplant recipients. Anti-CD25 induction therapy appears to be helpful to prevent the development of PTLD among Taiwanese renal transplant recipients.
authors.affiliation: Kidney Transplantation Program, Chang Gung Transplantation Institute, Taoyuan, Taiwan. zorro@cgmh.org.tw
authors.forename: Y J
authors.initials: YJ
authors.lastname: Chiang
authors.forename: H H
authors.initials: HH
authors.lastname: Wang
authors.forename: K L
authors.initials: KL
authors.lastname: Liu
authors.forename: S H
authors.initials: SH
authors.lastname: Chu
authors.forename: W C
authors.initials: WC
authors.lastname: Lee
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000453:epidemiology*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000453:epidemiology*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D013624:Taiwan; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents